Antioxidant News and Research

RSS

Antioxidants are substances that protect cells from the damage caused by free radicals (unstable molecules made by the process of oxidation during normal metabolism). Free radicals may play a part in cancer, heart disease, stroke, and other diseases of aging. Antioxidants include beta-carotene, lycopene, vitamins A, C, and E, and other natural and manufactured substances.

AVRF and UPEI collaboration awarded Innovation PEI Pilot and Discovery Fund grant

Atlanta Vascular Research Foundation (AVRF), together with its collaborators at the University of Prince Edward Island (UPEI), has been awarded an Innovation PEI Pilot and Discovery Fund grant by Innovation PEI. The grant is to continue research and development in combining nutraceuticals to magnify clinical benefits for the prevention and treatment of cardiovascular and metabolic diseases. The funding from this grant is $25,000.

27 Jan 2011

Two studies explore relationship between nutrition and asthma

Asthma is one of the world's most common chronic diseases, affecting as many as 300 million people. It is estimated that by 2025 there could be an additional 100 million people with the disease. This rapid increase in asthma is most likely due to changing environmental or lifestyle factors, and over the last 15 years, changing diet has emerged as a promising contributor. Two studies published in the in the February 2011 issue of the Journal of the American Dietetic Association explore the possible relationship between nutrition and asthma.

24 Jan 2011

Porter Adventist Hospital offers tips for healthier eating habits

It's now been a few weeks since we have made our New Year's resolutions to eat better and finally lose those last five pounds or more. It's time to check in and see if you've set yourself up for success this year. Brittany Glassett, registered dietitian at Porter Adventist Hospital has a few tips to keep in mind when setting - and keeping - new goals.

21 Jan 2011

Antioxidants may cause fertility problems in females

Antioxidants are sold over the counter everywhere. They're added to food, drink and face cream. But according to Prof. Nava Dekel of the Biological Regulation Department, we still don't have a complete understanding of how they act in our bodies. New research by Dekel and her team, recently published in the Proceedings of the National Academy of Sciences USA (PNAS), has revealed a possible unexpected side effect of antioxidants: They might cause fertility problems in females.

19 Jan 2011

Nutriceuticals may restore age-related vision loss

While age-related vision loss of catastrophic proportions is predicted in coming decades, rising from 17 million patients today to 55 million by the year 2050, it's possible this catastrophe could be averted and lost vision even restored using molecular medicine.

11 Jan 2011

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

UCLA researchers have found that a protein that plays an important role in some antioxidant therapies may not be as effective due to additional mechanisms that cause it to promote atherosclerosis, or clogging of the arteries.

11 Jan 2011

Resveratrol stimulates expression of adiponectin hormone: Study

Resveratrol, a compound in grapes, displays antioxidant and other positive properties. In a study published this week, researchers at the UT Health Science Center San Antonio describe a novel way in which resveratrol exerts these beneficial health effects.

10 Jan 2011

Tips for healthy living

Terra Wellington has made a career educating the public on the importance of healthy living. Here she shares easy tips for improving your health as we enter the New Year.

6 Jan 2011

Heart researchers find no evidence of toxicity in Longevinex

It was Paracelsus, the Renaissance physician who first said "the dose makes the poison." So, you can drink too much wine, or ingest too much resveratrol, but in an unprecedented study, heart researchers report they couldn't find a toxic dose for Longevinex-, a resveratrol-based dietary supplement.

30 Dec 2010

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.

28 Dec 2010

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Three weeks of oral resveratrol or Longevinex- ingestion prior to an induced heart attack returned microRNA activity close to their pre-event levels in excised animal hearts. Among thousands of microRNA's studied, just six were attributed to exerting the majority of the gene-switching effects measured in the animal heart study - four microRNA optimally regulated by Longevinex- and two optimally by plain resveratrol.

28 Dec 2010

Growth hormone may be hazardous for middle aged and older people

A compound which acts in the opposite way as growth hormone can reverse some of the signs of aging, a research team that includes a Saint Louis University physician has shown. The finding may be counter-intuitive to some older adults who take growth hormone, thinking it will help revitalize them.

24 Dec 2010

Spirulina dietary supplement may provide clinical benefits for ALS patients

Nutritional supplementation with Spirulina, a nutrient-rich, blue-green algae, appeared to provide neuroprotective support for dying motor neurons in a mouse model of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, University of South Florida neuroscientists have found.

21 Dec 2010

Study on why whole orange is better than components

In time for Christmas, BYU nutritionists are squeezing all the healthy compounds out of oranges to find just the right mixture responsible for their age-old health benefits.

21 Dec 2010

OXIS International files patent application to strengthen Ergothioneine intellectual property portfolio

OXIS International, Inc., today announced that is has filed a patent application titled "Methods and Compositions Using Ergothioneine to Treat a Variety of Health Related Factors" with the U.S. Patent and Trademark Office (USPTO).

20 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

Multi-unit dwellings contribute to children's exposure to tobacco smoke

Children living in apartments are exposed to secondhand smoke even when no one smokes inside their own unit. This study, released online today by the journal Pediatrics, strongly suggests that housing type contributes to children's exposure to tobacco smoke, despite the best intentions of parents.

13 Dec 2010

OXIS introduces ErgoFlex for relief of joint pain

OXIS International, Inc. announces the market launch of ErgoFlex™, a unique new dietary supplement for the relief of joint pain. It is the first in a series of commercial products planned by OXIS. ErgoFlex is the only joint health complex containing the powerful antioxidant Ergothioneine (ERGO), and is specifically formulated to help the body fight the pain of joint inflammation and maintain optimal joint health.

7 Dec 2010

UCLA findings could lead to enhanced health supplements, progress on Parkinson's

The discovery by UCLA biochemists of a new method for preventing oxidation in the essential fatty acids of cell membranes could lead to a new class of more effective nutritional supplements and potentially help combat neurodegenerative disorders such as Parkinson's disease and perhaps Alzheimer's.

3 Dec 2010

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck today reported initial results from the Phase III study investigating the efficacy and safety of a treatment regimen including ISENTRESS® (raltegravir) Tablets once daily in treatment-naïve adult patients infected with HIV-1. ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve and treatment-experienced adults.

29 Nov 2010